Results 31 to 40 of about 121,509 (248)
Organoids in pediatric cancer research
FEBS Letters, EarlyView.Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley +1 more source
Chimeric antigen receptor–engineered T cells for liver cancers, progress and obstacles
Tumor Biology, 2017 Chimeric antigen receptor–engineered T cells therapy has become the hottest topic of immunotherapy, as its great successes achieved in treating refractory hematological malignancies.
Keyu Li +3 more
doaj +1 more source
Molecular Oncology, EarlyView.Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary +1 more
wiley +1 more source
Molecular Oncology, EarlyView.Single‐cell DNA methylation (scDNAme) profiling maps epimutational clonal evolution, revealing mechanisms of malignancy and therapeutic resistance across diverse cancer types. By providing a high‐resolution landscape of intratumoral heterogeneity, these technologies empower precise patient stratification, guide the development of enhanced ...
Ik Soo Kim
wiley +1 more source
Nature CommunicationsThe efficacy of Chimeric Antigen Receptor T cells against solid tumors is limited by immunosuppressive factors in the tumor microenvironment including adenosine, which suppresses Chimeric Antigen Receptor T cells through activation of the A2A receptor ...
Kevin Sek +35 more
doaj +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Just recently, successful chimeric antigen receptor (CAR) T cell therapy was reported in the first patient with refractory, anti‐diacylglycerol lipase alpha (DAGLA) antibody‐mediated autoimmune encephalitis, achieving partial clinical remission.
Dimitrios Mougiakakos +9 more
wiley +1 more source
Nano Biomedicine and EngineeringChimeric antigen receptor T cell therapy represents a transformative advancement in immunotherapy, wherein engineered T cells target tumor antigens, achieving high response rates in hematological malignancies.
Zhitong Guo, Mengjie Zhang, Yuanyu Huang
doaj +1 more source
Claustrum Involvement in New Onset Refractory Status Epilepticus: A Systematic Review
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT The claustrum sign is a distinctive neuroimaging finding characterized by bilateral T2/FLAIR hyperintensity of the claustrum, one of the most interconnected regions of the human brain. It was first described in new‐onset refractory status epilepticus (NORSE) and febrile infection–related epilepsy syndrome (FIRES).
Margherita Burani +5 more
wiley +1 more source
Chimeric Antigen Receptor-T Cell Therapy
HemaSphere, 2018 . Chimeric antigen receptor (CAR)-T cell therapy is a new class of cellular immunotherapies that involves ex vivo genetic modification of T cells to incorporate an engineered CAR.
Jochen Buechner +4 more
doaj +1 more source
Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity
Signal Transduction and Targeted Therapy, 2023 Ligand-induced receptor dimerization or oligomerization is a widespread mechanism for ensuring communication specificity, safeguarding receptor activation, and facilitating amplification of signal transduction across the cellular membrane.
Yan Sun +15 more
doaj +1 more source